Geode Capital Management LLC Has $9.21 Million Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Geode Capital Management LLC boosted its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 8.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 576,451 shares of the company’s stock after buying an additional 46,512 shares during the period. Geode Capital Management LLC owned approximately 1.54% of Entrada Therapeutics worth $9,214,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in TRDA. The Manufacturers Life Insurance Company boosted its position in shares of Entrada Therapeutics by 3.9% during the second quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock worth $814,000 after buying an additional 2,146 shares during the period. US Bancorp DE acquired a new position in Entrada Therapeutics during the 3rd quarter worth approximately $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Entrada Therapeutics by 34.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock worth $226,000 after acquiring an additional 3,644 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Entrada Therapeutics by 25.3% in the second quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after purchasing an additional 7,452 shares during the last quarter. Finally, Public Employees Retirement System of Ohio lifted its position in shares of Entrada Therapeutics by 89.1% in the third quarter. Public Employees Retirement System of Ohio now owns 16,259 shares of the company’s stock worth $260,000 after purchasing an additional 7,659 shares in the last quarter. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Entrada Therapeutics news, CFO Kory James Wentworth sold 5,000 shares of Entrada Therapeutics stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $20.00, for a total value of $100,000.00. Following the transaction, the chief financial officer now owns 73,849 shares in the company, valued at $1,476,980. The trade was a 6.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $20.77, for a total transaction of $476,359.95. Following the completion of the transaction, the insider now directly owns 4,402,849 shares of the company’s stock, valued at $91,447,173.73. This trade represents a 0.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,281 shares of company stock valued at $861,999 over the last 90 days. 7.59% of the stock is owned by corporate insiders.

Entrada Therapeutics Stock Down 0.5 %

Shares of Entrada Therapeutics stock opened at $17.29 on Thursday. Entrada Therapeutics, Inc. has a twelve month low of $11.35 and a twelve month high of $21.79. The company has a 50-day simple moving average of $18.54 and a two-hundred day simple moving average of $16.78. The stock has a market capitalization of $646.99 million, a price-to-earnings ratio of 10.87 and a beta of -0.18.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TRDA. Oppenheimer raised their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th. Roth Capital raised shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. HC Wainwright boosted their target price on Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Finally, Roth Mkm assumed coverage on Entrada Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $29.00 price target for the company.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.